DrugBiological
Brodalumab clinical trials
Also written AMG 827, Siliq and KHK4827.
- studies test it
- 43
- open now
- 1
- in phase 3
- 14
- first study started
- 2008
Keep track of what changes. Save the brodalumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Studies by the year they started
43 studies that test it; most in 2012 (5)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 4 |
| 2011 | 3 |
| 2012 | 5 |
| 2013 | 4 |
| 2014 | 4 |
| 2016 | 1 |
| 2017 | 5 |
| 2018 | 1 |
| 2019 | 4 |
| 2020 | 5 |
| 2021 | 2 |
| 2022 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 3
- Phase 1
- 6
- Phase 2
- 11
- Phase 3
- 14
- Phase 4
- 10
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 34 · Other 9
Kyowa Kirin Co., Ltd. (11) · Bausch Health Americas, Inc. (10) · Amgen (7) · LEO Pharma (4) · Rockefeller University (3) · Radboud University Medical Center (1) · Kyowa Kirin Korea Co., Ltd. (1) · Icahn School of Medicine at Mount Sinai (1)
Often tested with
Tested in the same studies.
Secukinumab (1) · Ixekizumab (1) · Guselkumab (1) · Risankizumab (1) · Tildrakizumab (1) · Bimekizumab (1)
Studies
Open first, then newest update. How each study uses brodalumab is read from its arms, and is right about nine times in ten.
Testing it · 43
- Brodalumab in the Treatment of Immune-Related Adverse EventsRecruitingPhase 1Brian Henick, MDNCT06673329Written as Brodalumab
- Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body WeightCompletedPhase 4LEO PharmaNCT04306315Written as Brodalumab
- Dose Reduction of IL17 and IL23 Inhibitors in PsoriasisCompletedPhase 4Radboud University Medical CenterNCT04340076Written as Brodalumab
- An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric SubjectsActive, not recruitingPhase 4Bausch Health Americas, Inc.NCT03240809Written as Brodalumab
- A Phase 3 Study of KHK4827 in Patients With Systemic SclerosisCompletedPhase 3Kyowa Kirin Co., Ltd.NCT03957681Written as KHK4827
- A Study of KHK4827 in Patients With Systemic SclerosisCompletedPhase 1Kyowa Kirin Co., Ltd.NCT04368403Written as KHK4827
- Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque PsoriasisTerminatedPhase 3LEO PharmaNCT04305327Written as Brodalumab
- Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to UstekinumabTerminatedPhase 4LEO PharmaNCT04533737Written as Brodalumab
- A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque PsoriasisCompletedPhase 4LEO PharmaNCT03331835Written as Brodalumab
- A Study of Brodalumab in Subjects With Axial Spondyloarthritis (axSpA)CompletedPhase 3Kyowa Kirin Co., Ltd.NCT02985983Written as Brodalumab
- A Study of KHK4827 (Brodalumab) in Subjects With Moderate to Severe Psoriasis in KoreaCompletedPhase 3Kyowa Kirin Korea Co., Ltd.NCT02982005Written as KHK4827
- A Phase 3 Clinical Study of KHK 4827CompletedPhase 3Kyowa Kirin Co., Ltd.NCT02052609Written as KHK4827 140mg SC
- A Study of KHK4827 in Subjects With Palmoplantar PustulosisCompletedPhase 3Kyowa Kirin Co., Ltd.NCT04061252Written as KHK4827
- Study of Efficacy and Safety of Brodalumab Compared With Placebo in Adults With Inadequately Controlled Asthma With High Bronchodilator ReversibilityTerminatedPhase 2AmgenNCT01902290Written as Brodalumab
- Molecular Characteristics of Brodalumab in Hidradenitis SuppurativaCompletedEarly Phase 1Rockefeller UniversityNCT04979520Written as Brodalumab
- Safety and Efficacy of AMG 827 in Subjects With RATerminatedPhase 2AmgenNCT01059448Written as AMG 827
- Brodalumab (AMG 827) in Adults With Moderate to Severe Crohn's DiseaseTerminatedPhase 2AmgenNCT01150890Written as Brodalumab
- Long-term Safety Study of Brodalumab in Adults With Crohn's DiseaseTerminatedPhase 2AmgenNCT01199302Written as Brodalumab
- Brodalumab (AMG 827) in Rheumatoid Arthritis (RA) Participants With Inadequate Response to MethotrexateCompletedPhase 2AmgenNCT00950989Written as Brodalumab
- Study to Evaluate the Safety, PK, PD and Efficacy of AMG 827 in Adults With Rheumatoid ArthritisCompletedPhase 1/2AmgenNCT00771030Written as Brodalumab
Codes
What other systems call brodalumab · ClinicalTrials.gg INT006025
- MeSH (NLM) C571216brodalumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 6ZA31Y954ZBRODALUMABConfirmed FDA, NLM, Wikidata
- RxNorm 1872251Confirmed FDA, Wikidata
- Wikidata Q4972934brodalumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166971BrodalumabOne source FDA
- DrugBank DB11776One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C571216 | brodalumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 6ZA31Y954Z | BRODALUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1872251 | — | Confirmed FDA, Wikidata |
| Wikidata | Q4972934 | brodalumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166971 | Brodalumab | One source FDA |
| DrugBank | DB11776 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.